For older patients with type 2 diabetes mellitus, higher levels of seroprotection against the hepatitis B virus were obtained following the receipt of the 2-dose vaccine vs the 3-dose vaccine.
Researchers suggest that the hepatitis E virus remains a worldwide threat because more needs to be investigated about its transmission.
Investigators found that young age, high HCV viral load, and HCV/HIV co-infection were the factors associated with an increased transmission risk.
Researchers found data that showed entecavir is safe in the treatment of hepatitis B virus in patients who are undergoing hemodialysis.
Researchers found data that showed early initiation of antiviral therapy with lamivudine in infants with hepatitis B caused a rapid loss of HBsAg.
Researchers found data that showed in patients with hepatitis C, the presence of resistance-associated substitutions did not change the sustained viral response after treatment failure with other direct-acting-antivirals with the combination of sofosbuvir, velpatasvir, and voxilaprevir.
Researchers found data that showed in pregnant women with hepatitis B, the antiviral medications telbivudine and tenofovir disoproxil fumarate were safe, effective, and well tolerated, while reducing transmission of hepatitis B from mother to child during the perinatal period.
Researchers explore factors that surround creating a vaccine to combat hepatitis C virus infection.
Researchers found data that showed chronic hepatitis C virus infection and associated carotid intima-media thickness and plaque are predictors for cerebrovascular disease.
In China, researchers found data that showed that patients with HBsAg seropositive test results were at an increased risk of developing hepatocellular carcinoma, stomach cancer, oral cancer, colorectal cancer, pancreatic cancer, and lymphoma.
Two studies on hepatitis A and hepatitis B vaccination highlight opportunities to improve coverage of ≥2 doses of hepatitis A vaccine in children and hepatitis B vaccine series completion in adults.
Hepatitis E seropositivity is higher in older adults and may represent an increased exposure risk over time; in contrast, the opioid crisis has caused a demographic shift in hepatitis C infection, which is now a predominately millennial disease.
Direct-acting antiviral agents for treatment of hepatitis C virus may have higher sustained virologic responses in people coinfected with hepatitis B and hepatitis C viruses.
Among women giving birth, the rates of hepatitis C virus (HCV) infection increased more than 400 percent from 2000 to 2015, with rates much higher among those with opioid use disorder.
A novel, and newly licensed hexavalent vaccine, comprising DTaP, IPV, Hib and HepB vaccines, may allow for simplification of administering and adhering to recommendations for infant vaccine series.
Gaps in care for patients with hepatitis C infection and possible interventions were explored in interviews with several doctors.
In a clinical practice guideline, updated recommendations are presented for the prevention, diagnosis, treatment, and management of hepatitis C virus (HCV) infection in adults with chronic kidney disease.
Researchers found data from that showed the once-daily, direct-acting antiviral regimen, glecaprevir co-formulated with pibrentasvir, is effective and safe in hepatitis C.
Researchers found data that showed among patients who are HIV positive, hepatitis E viral transmission is unrelated to sexually transmitted disease.
After expanding, freezing, thawing and re-culturing novel wild-type isolates of hepatitis E, investigators in Europe observed what they categorized as an unlimited production of hepatitis E virus during a period of 2 years, which they believe will allow in vitro testing for the effectiveness of sofosbuvir in combination with ribavirin or silvestrol.